Nexalin Technology, Inc. announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device has been granted regulatory approval by the Brazilian Health Regulatory Agency, a regulatory body of the Brazilian government responsible for approving new drugs and medical devices.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.825 USD | -38.34% |
|
+10.98% | +349.60% |
03:17pm | Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation | MT |
02:08pm | Investors Await Key Inflation Data as US Futures Trend Higher Pre-Bell | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
5.958 BRL | +1.08% | +2.62% | - | ||
1.825 USD | -38.34% | +10.98% | 22.01M | ||
1st Jan change | Capi. | |
---|---|---|
+349.60% | 22.01M | |
+4.21% | 210B | |
+8.84% | 186B | |
+31.80% | 158B | |
+33.42% | 113B | |
+2.28% | 66.13B | |
+22.22% | 56.25B | |
+0.11% | 49B | |
-5.50% | 38.16B | |
+1.20% | 35.98B |
- Stock Market
- Equities
- NXL Stock
- News Nexalin Technology, Inc.
- Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 MA Neurostimulation Device by the Brazilian Health Regulatory Agency